Studies show that antidepressants don’t always work. One psychologist explains how to take control of negative thoughts ...

Shares of the biotech Neumora Therapeutics began the first trading day of 2025 with a loss of more than 80% after the company ...

Treating ADHD is straightforward with stimulants, often giving patients life-changing relief. But with comorbid conditions, ...

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

Neuroscience company Neumora Therapeutics (NMRA) announced today that its experimental treatment for depression, Navacaprant, ...

In zebrafish, ketamine causes changes a brain circuit involved in "giving up." That may help explain how the drug helps ...

To treat depression, the tech magnate has said he'd rather use ketamine, a dissociative anesthetic, than traditional antidepressants.

A recent study analyzing data from the National Survey on Drug Use and Health (NSDUH) found that past-year recreational ketamine use among adults has increased dramatically since 2015, including ...

Neumora Therapeutics, Inc. (NASDAQ:NMRA) stock traded lower after the company released data from the Phase 3 KOASTAL-1 Study ...

According to a new study, ketamine use has risen significantly since 2015. The results highlight the need for closer monitoring of recreational ketamine use.

Thomas Trutschel / Photothek via Getty Images Neumora Therapeutics reported its experimental depression drug didn't meet expectations, and shares plunged. The biopharmaceutical firm's navacaprant ...